Search results
Showing 646 to 660 of 2106 results for technology appraisal
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
In development Reference number: GID-TA11509 Expected publication date: 24 February 2027
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.
Our HealthTech Programme considers technologies that could offer benefits to patients and the health and social care system over current practice.
In development Reference number: GID-TA10575 Expected publication date: 05 August 2026
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
Awaiting development Reference number: GID-TA11535 Expected publication date: TBC
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Awaiting development Reference number: GID-TA11658 Expected publication date: TBC